Mesoblast Company Profile (NASDAQ:MESO)

Analyst Ratings

Consensus Ratings for Mesoblast (NASDAQ:MESO) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $8.63 (100.58% upside)

Analysts' Ratings History for Mesoblast (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Maxim GroupReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$10.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$9.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Chardan CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Mesoblast (NASDAQ:MESO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/16/2016Q216($0.06)$30.00 million$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/16/2015Q116($0.04)$7.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mesoblast (NASDAQ:MESO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Mesoblast (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Mesoblast (NASDAQ:MESO)
DateHeadline
07/21/16 05:24 PMBanks, health stocks rally: Aus shares up 0.6% at lunch
07/20/16 08:02 AMBone Marrow Transplant Industry Worth $15.95 Billion By 2022 According to Global Market Research Report
07/19/16 05:15 PMASX 200 lifts for eight straight sessions on brighter outlook - Motley Fool Australia
07/18/16 05:17 PMMarket Wrap: Aus shares close 0.53% higher
07/14/16 08:44 AMBone Marrow Transplant Market Growth, Trends and Value Chain 2016-2026 by FMI
07/10/16 04:38 PMMesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming Week - Fiscal Standard
07/07/16 08:02 AMOverview of Stem Cell Therapy Market: Growing at 39.5% CAGR to 2020 (Executive Summary, Industry Insights and Compnay Profiles)
07/04/16 04:35 PMMesoblast limited moves to reassure investors - Motley Fool Australia
07/04/16 09:54 AMMesoblast limited moves to reassure investors
07/02/16 07:57 AMMesoblast Limited: Update on Heart Failure Trial and Funding of Operations - The Wall Street Transcript
07/02/16 07:57 AMMesoblast Limited (NASDAQ:MESO) Current Analyst Ratings - Fiscal Standard
07/01/16 07:57 AMAustralia, NZ shares extend rally to recover Brexit losses
07/01/16 07:57 AMMarket Wrap: Aus shares close 0.26% higher
07/01/16 07:57 AMMesoblast Provides Update on Heart Failure Trial and Funding of Clinical Operations
06/29/16 05:00 PMNew Broker Ratings For Mesoblast Limited (NASDAQ:MESO) - FTSE News
06/28/16 05:01 PMMesoblast limited (ADR) on Focus After Trading At 52-Week Lows - Engelwood Daily
06/27/16 09:28 AMNext Weeks Broker Price Targets For Mesoblast Limited (NASDAQ:MESO) - Fiscal Standard
06/22/16 09:51 AMCredit Suisse Downgrades Mesoblast limited (ADR) to Neutral with Price Target $5.00 - Trade Calls
06/16/16 09:25 AMMesoblast Ltd (NASDAQ:MESO) Receives 'Neutral' Rating From Brokers At Credit Suisse - FTSE News
06/15/16 05:05 PMWhy have Mesoblast Limited shares soared today? - Motley Fool Australia
06/15/16 05:05 PMThere could be more pain ahead for Mesoblast limited as credibility sinks - Motley Fool Australia
06/15/16 09:46 AMWhy have Mesoblast Limited shares soared today?
06/14/16 04:55 PM5 Stocks That Are Exhibiting Heightened Volatility Today
06/14/16 04:55 PMThere could be more pain ahead for Mesoblast limited as credibility sinks
06/14/16 04:55 PMMesoblast Downgraded To Neutral, Target Price Cut In Half
06/14/16 04:55 PMSynchrony Financial, Wells Fargo and Navistar slip
06/14/16 04:55 PMSynchrony Financial, Wells Fargo and Navistar slip
06/14/16 04:55 PMMesoblast : Teva ends collaboration with Australian co Mesoblast
06/14/16 04:55 PMMesoblast slumps 36% premarket after Teva backs out of MPC-150-IM development
06/14/16 04:55 PMMesoblast Limited (MESO) Regains Worldwide Right to MPC Technology Platform
06/14/16 01:34 PM9 Biggest Mid-Day Losers For Tuesday -   Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dipped 70.63 percent to $1.29. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint. Mesoblast limited (ADR) (NASDAQ: MESO) shares fell 36.03 percent to $4.52 as the company issued an update on global heart failure program. The company reported that it has regained rights to cardiovascular field for cell therapy platform. KemPharm Inc (NASDAQ: KMPH) shares fell 26.23 ...Full story available on Benzinga.com
06/14/16 09:54 AMCRASH! Mesoblast limited shares plunge 42% - Motley Fool Australia
06/14/16 09:54 AMCredit Suisse Downgrades Mesoblast Limited (MESO) to Neutral - StreetInsider.com
06/14/16 09:54 AMMesoblast Limited (MESO) Regains Worldwide Right to MPC Technology Platform - StreetInsider.com
06/14/16 05:16 AMMesoblast downgraded by Credit Suisse -
06/14/16 05:00 AM6:00 am Mesoblast provides update on global heart failure program; regains rights to cardiovascular field for cell therapy platform; FDA approved second navigational catheter system (halted since June 1) -
06/10/16 05:22 PMMesoblast Limited: Extension of Voluntary Suspension - The Wall Street Transcript
06/10/16 08:05 AMExtension of Voluntary Suspension - irasia.com (press release)
06/10/16 08:05 AMMesoblast limited could be about to sink or soar - Motley Fool Australia
06/07/16 05:19 PMAdult Stem Cells Global Market Professional Survey Report 2016
06/06/16 08:50 AMMesoblast limited's (MESO) Buy Rating Reiterated at Maxim Group - Let Me Know About This
06/03/16 07:55 AMMesoblast limited trading halt leaves investors guessing - Motley Fool Australia - Mesoblast limited trading halt leaves investors guessingMotley Fool AustraliaRegenerative medicine business Mesoblast limited (ASX: MSB) has requested more time before it makes an announcement to the market regarding 'material corporate developments with respect to certain assets of the company'. The shares were ...
06/01/16 07:58 AMMesoblast limited trading halt leaves it on the edge - Motley Fool Australia - Mesoblast limited trading halt leaves it on the edgeMotley Fool AustraliaShares in regenerative medicine business Mesoblast limited (ASX: MSB) are locked in a trading halt this afternoon with the company set to announce “material corporate developments with respect to certain assets of the company”. Although the company is ...and more »
05/30/16 08:07 PMAfter Last Week What Do Analysts Think Of Mesoblast Limited (NASDAQ:MESO) - Share Trading News - After Last Week What Do Analysts Think Of Mesoblast Limited (NASDAQ:MESO)Share Trading News03/07/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 10 price target on the stock. 02/19/2016 – Chardan Capital began new coverage on Mesoblast Limited giving the company a “neutral” rating.and more »
05/25/16 09:44 AMMesoblast limited Declines A lot Today, Is Now One of The Worst Performer - Wall Street Hints and News - Mesoblast limited Declines A lot Today, Is Now One of The Worst PerformerWall Street Hints and NewsThe stock of Mesoblast limited (ASX:MSB) is a huge mover today! The stock is down 2.97% or $0.06 after the news, hitting $1.96 per share. About 518,773 shares traded hands. Mesoblast limited (ASX:MSB) has declined 40.06% since October 27, 2015 and is ...and more »
05/23/16 09:50 AMMesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming Week - Share Trading News - Mesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Mesoblast Limited (NASDAQ:MESO). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/21/16 09:53 AMLatest Analyst Ratings For Mesoblast Limited (NASDAQ:MESO) - Share Trading News - Latest Analyst Ratings For Mesoblast Limited (NASDAQ:MESO)Share Trading News03/07/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 10 price target on the stock. 02/19/2016 – Chardan Capital began new coverage on Mesoblast Limited giving the company a “neutral” rating.
05/21/16 09:53 AMRevenue Update on Mesoblast limited (ADR)(NASDAQ:MESO) - Trade Calls - Revenue Update on Mesoblast limited (ADR)(NASDAQ:MESO)Trade CallsMesoblast limited (ADR)(NASDAQ:MESO) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 9, 2016. Company reported revenue of $4.14M. Analysts estimated a revenue of $36.73M. Earnings per ...
05/20/16 09:48 AMMesoblast receives $6.2M for R&D - Mesoblast Limited (ASX:MSB) has announced it has received $6.2 million from the Australian Government. The funding is for activities conducted in the 2015 financial year, and was provided under the Government’s R&D Tax Incentive Program. Mesoblast ...
05/20/16 09:48 AMMesoblast : Receives $6.2m From Aus Govt For R&D - Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it has received $6.2 million from the Australian Government for Research & Development (R&D) activities conducted during the 2015 financial year. The funds were provided to Mesoblast under the ...

Social

About Mesoblast

Mesoblast logoMesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates, which represents its lead programs where it focuses on time and resources, such as MPC-06-ID, MPC-150-IM, JR-031, MPC-300-IV and MSC-100-IV, and tier 2 product candidates, which advances to tier 1 depending on newly-generated data, market opportunity or partnering options, such as MSC-100-IV, MPC-25-IC, MPC-25-Osteo and MPC-CBE.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MESO
  • CUSIP:
Key Metrics:
  • Previous Close: $4.30
  • 50 Day Moving Average: $4.66
  • 200 Day Moving Average: $6.72
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $324.33M
  • Beta: 2.96
  • Current Year EPS Consensus Estimate: $-0.57 EPS
  • Next Year EPS Consensus Estimate: $-0.72 EPS
Additional Links:
Mesoblast (NASDAQ:MESO) Chart for Monday, July, 25, 2016